US STOCKS-Wall St stumbles as Trumps comments hit healthcare stocks


Warning: This material has been prepared by a third party company, Reuters, which is independent of Davy. Davy has not reviewed the material and accepts no responsibility for errors or omissions, or for the information or opinions contained therein. It does not constitute investment advice.

* Health stocks drop after Trump comments on drug pricing * Dow up 0.02 pct, S&P down 0.23 pct, Nasdaq down 0.37 pct (Adds details on Trump speech, updates prices) By Yashaswini Swamynathan Jan 11 (Reuters) - U.S. stocks slipped on Wednesday, weighed down by healthcare stocks after President-elect Donald Trump commented on the need for competitive drug pricing in his first formal news conference after his victory. Investors are closely watching Trump's speech, looking for clues on where his priorities as the new president lie, after taking office on Jan. 20 and how he plans boost economic growth. Eight of the 11 major S&P sectors were lower. The healthcare sector .SPXHC dropped 0.787 percent after Trump said the country needs more competitive drug bidding. He said pharmaceutical companies are "getting away with murder" by charging high drug prices. Lockheed Martin LMT.N dropped about 1 percent after Trump said the F-35 fighter jet project "is way behind schedule and billions over budget." At 11:33 a.m. ET (1633 GMT), the Dow Jones Industrial Average .DJI was up 3.99 points, or 0.02 percent, at 19,859.52, the S&P 500 .SPX was down 5.26 points, or 0.23 percent, at 2,263.64 and the Nasdaq Composite .IXIC was down 20.77 points, or 0.37 percent, at 5,531.05. (Reporting by Yashaswini Swamynathan in Bengaluru; Editing by Savio D'Souza) ((; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 2405; Reuters Messaging: Keywords: USA STOCKS/

Warning: This content may be provided by regulated and unregulated entities and is not created, reviewed or endorsed by Davy. It is provided for general information purposes only and does not constitute a recommendation or solicitation to purchase or sell any security or make any other type of investment or investment decision. Importantly, it does not constitute investment advice, as it does not contemplate the personal circumstances of any particular person or group of persons. Neither Davy nor the providers of the Third Party Content will be liable for any investment decision made based on the reliance on or use of such data, or any liability that may arise due to delays or interruptions in the delivery of the Third Party Content for any reason.